Page 47 - Compugen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Compugen Reports First Quarter 2021 Results USA - English Updated data from COM701 Phase 1 combination and monotherapy studies to be presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting Milestone rich 2021 to include data readouts from ongoing COM701 triple combination study and COM902 monotherapy study in Q4 2021 Initiation of Phase 1b cohort expansion study of COM701 with Opdivo® in Q2 2021 and Phase 1 COM701 with COM902 dual combination study in 2H 2021 will expand systematic DNAM axis clinical evaluation News provided by Share this article Share this article ...

Compugen Announces Expansion of Research Collaboration with Johns Hopkins University for a Novel Myeloid Target Discovered by Compugen USA - English News provided by Share this article HOLON, Israel, May 10, 2021 /PRNewswire/ --  Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it has expanded its research collaboration with Johns Hopkins University to include studies investigating the biology of a novel myeloid target that was computationally-discovered by Compugen. Initial preclinical studies demo...

GuruFocus Article or News written by PRNewswire and the topic is about:

Pandemic-fueled innovation highlighted at 2021 channel conference and awards Published: April 28th, 2021 By: ITWC April 28, 2021, TORONTO – Seven Canadian channel organizations were celebrated today for the creation and deployment of novel solutions solving pressing problems during the CDN 2021 Channel Innovation Conference and Awards. The virtual event also saw the release of the annual CDN Top 100 Solution Providers ranking, a listing of channel organizations that collectively generated more than $10 billion in revenue during 2020. Channel organizations are a unique and valuable part of ...

Compugen Publishes Preclinical Data Demonstrating Therapeutic Potential of COM902 in Cancer Immunology, Immunotherapy USA - English Peer reviewed data demonstrate synergistic effect of anti-TIGIT antibody, COM902, with PVRIG and PD-1 blockade for the treatment of cancer Phase 1 trial of COM902 monotherapy in patients with advanced malignancies is currently on track to report data in Q4 2021; Initiation of dual combination study for COM701 with COM902 expected as planned in H2 2021 News provided by Share this article HOLON, Israel, April 27, 2021 /PRNewswire/ -- Cancer Immunology, Immunothera...